Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Orbofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.93 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.93 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 9/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 9/20 | 0.47 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orbofiban SCHEMBL7417473 | 0.99 | ITGB3 (0.95) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7854981 | 0.96 | ITGB3 (1.00) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7415135 | 0.96 | ITGB3 (1.00) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7411884 | 0.92 | ITGB3 (0.88) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7444902 | 0.89 | ITGB3 (0.86) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Acetic Acid SCHEMBL7418342 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7451885 | 0.88 | ITGB3 (0.84) | ITGB3ITGA2BFPR1FPR2 | |
| Hydrochloric Acid SCHEMBL7452981 | 0.88 | ITGB3 (0.81) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7448694 | 0.88 | ITGB3 (0.83) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7446820 | 0.88 | ITGB3 (0.80) | ITGB3ITGA2BPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | ITGB3 4489/4885ITGA2B 4400/4885PRSS1 1768/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | ITGB3 3923/4885ITGA2B 4119/4885PRSS1 2510/4885 |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ITGB3 2339/4885ITGA2B 2056/4885PRSS1 545/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | ITGB3 4568/4885ITGA2B 4625/4885PRSS1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.